Results 141 to 150 of about 27,792 (251)
Roadmap for Mental Health Treatment Utilizing Pharmacogenomic Testing: Case Report
Clinical Case Reports, Volume 14, Issue 9, September 2026.
Allison P. Swanson +2 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.ABSTRACT This study quantified age‐related differences in fluoxetine pharmacokinetics and evaluated the influence of CYP2D6 phenotype using physiologically based pharmacokinetic (PBPK) modeling integrated with clinical therapeutic drug monitoring data.
Yoo Jin Jang +2 more
wiley +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.ABSTRACT Accurate physiologically based pharmacokinetic (PBPK) simulation of drug–drug interaction (DDI) potential requires estimation of the relative contribution of the impacted pathway. While fraction metabolized by CYP enzymes is usually estimated using dedicated clinical DDI studies with strong CYP inhibitors, this approach might not be available ...
Ian E. Templeton +6 more
wiley +1 more source
CYP2C19*2 polymorphism and clopidogrel resistance [PDF]
Archivos de cardiolog�a de M�xico (English ed. Internet), 2021 Beuy, Joob, Viroj, Wiwanitkit
openaire +2 more sources
Anaesthesia, Volume 81, Issue 9, Page 1236-1244, September 2026.Summary Introduction Patients who require major vascular surgery often receive antiplatelet therapy for primary or secondary prevention of cardiovascular disease. Clopidogrel resistance and variability in platelet recovery after drug discontinuation pose clinical challenges, particularly for regional anaesthesia and blood management.
Akshay Shah +11 more
wiley +1 more source
Chemical Biology &Drug Design, Volume 108, Issue 3, September 2026.Rational Design, Synthesis, Biological Evaluation, and In Silico Investigation of N‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting Wild‐Type and Mutant EGFR in NSCLC. ABSTRACT Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor ...
Rohit Pal +6 more
wiley +1 more source
Clinical and Translational Science, Volume 19, Issue 9, September 2026.ABSTRACT Cendakimab is a humanized monoclonal antibody that inhibits interleukin‐13 binding to its receptors. Although not expected to share clearance pathways with small molecules, its use in eosinophilic esophagitis, a type 2 inflammatory disease, may indirectly affect cytochrome P450 activity by modulating cytokine signaling affecting certain ...
Peijin Zhang +10 more
wiley +1 more source